Science 37 (SNCE)

Executive Summary

Science 37 is a pioneering company in decentralized clinical trials (DCTs), offering a platform that enables remote patient participation and expands access to diverse populations. Founded in 2014 and headquartered in Los Angeles, the company has established itself as a leader in hybrid and virtual trial solutions. By leveraging its direct-to-patient model, Science 37 reduces trial timelines, lowers costs, and improves recruitment and retention rates, addressing key inefficiencies in traditional clinical research. The company serves a broad range of pharmaceutical and biotech clients, supporting trials across various therapeutic areas. Despite a competitive landscape and recent market headwinds, Science 37's technology and operational expertise position it well for long-term growth as DCT adoption accelerates. Looking ahead, Science 37 is focused on scaling its platform and expanding its client base. The company has been investing in AI-driven patient matching and data analytics to enhance trial efficiency. Additionally, it is pursuing international expansion, particularly in Europe and Asia, to capture a larger share of the global clinical trial market. While the company was taken private in 2023, it continues to operate with a strong balance sheet and a clear strategic vision. With the increasing demand for decentralized solutions post-pandemic, Science 37 is well-positioned to capitalize on the shift toward patient-centric clinical research, though execution risks remain in a crowded market.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership Announcement65% success
• Q4 2026European Expansion Milestone (e.g., first trial in EU)70% success
• Q2 2027Achieving Positive EBITDA50% success